Braveheart Bio (NASDAQ: BRVE) just raised $440 million to list on the Nasdaq. It was founded two years ago, and its primary drug treats a heart condition where the muscle thickens and struggles to pump.

Braveheart didn`t invent the drug, they licensed it from a pharmaceutical company in China, every clinical trial so far was designed and run entirely by that Chinese company. Braveheart wasn`t involved and doesn`t manufacture the drug. What Braveheart bought was the exclusive right to seek FDA approval and sell the drug everywhere, except Greater China.

There have been more than one hundred similar licensing deals since the start of last year. Increasingly, cutting-edge medicines are invented in China and sold to you by American biotechs.

#biotech #stocks #nasdaq #IPO #fintok

Patrys (ASX:PAB) is advancing its lead drug candidate, RLS-2202, towards its first clinical trial in humans. During the June quarter, Patrys appointed a specialist clinical trial site and contract research organisation, progressed its trial protocol and submitted its ethics application. The company is now targeting first participant dosing in Q3 2026, subject to the required approvals. Patrys CEO Dr Samantha South joins The Stock Network`s Lel Smits to discuss RLS-2202, the company`s path into the clinic and what investors can expect next.

⚕️ Getting RLS-2202 into the clinic
🔬 What RLS-2202 could do
🚀 What`s next for Patrys

Who is winning the weight loss boom? It`s not the company that makes Ozempic. It`s Eli Lilly And Co (NYSE:LLY), which makes Ozempic`s biggest rival, Mounjaro.

Mounjaro and its sister product were about two-thirds of everything Lilly sold in the second quarter with total revenue rising 48% to was $23 billion over the last year.

Here`s the strange part - Lilly`s prices went down, while it sold 60 per cent more and charged 13 per cent less. That`s what a boom actually looks like: not charging more but reaching more people.

#money #health #stocks #GLP1 #weightloss

Osteopore (ASX:OSX) has expanded its orthopaedic bone reconstruction business into the Middle East after signing a three-year distribution agreement with Al-Umnia Medical covering five Gulf Cooperation Council (GCC) markets.

🦴 Regional expansion: The agreement covers Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain, with Osteopore and Al-Umnia now progressing product registrations across the five countries.
🌍 Large addressable market: The GCC orthopaedic devices market was valued at approximately US$897.5 million in 2025 and is forecast to reach US$1.55 billion by 2034, according to cited market research.
🤝 Established partner: Dubai-based Al-Umnia has grown from a four-person team in 2009 to more than 70 employees, with a focus on medical technology partnerships, clinical education, training and support across the GCC.

"Our orthopaedics bone reconstruction product line is now progressing to the next phase of commercialisation – beyond South East Asia to the Middle East." – Dr Yujing Lim, Osteopore CEO

ADHD rates are soaring and one ASX company founded by Princeton neuroscientists, wants to change that. BlinkLab’s (ASX:BB1) smartphone app used the phone`s camera to measure involuntary responses like blinking.

A recent European study showed it correctly identified 82 per cent of the children who had an ADHD diagnosis, and correctly cleared 83 per cent of those who didn`t.

It`s early research but if you`ve ever waited months for a specialist appointment, you know why someone`s trying. The idea isn`t to replace the specialist. It`s to work out who needs one first.

#finance #health #stocks #ADHD #fintok

What`s a lockup and why does it matter to SpaceX Space Exploration Technologies Corp. (SPCX) shareholders? When a company lists, early investors such as founders, staff and venture funds agree to hold their shares for a set period. The reason is simple. Nobody would want to invest in a company if insiders could cash out the next morning.

SpaceX listed in June, in the biggest IPO ever. Now the first lockup period is ending, and over 900 million more shares can be sold by those early holders. If enough of them decide to cash out, this could put even more pressure on SpaceX`s share price. It’s worth knowing whenever you see a hot new listing. There’s a second date, months later, that nobody puts in the headline.

#fintok #elonmusk #spaceX #money #investing

Argent BioPharma (ASX:RGT) is advancing the expansion of its CannEpil® platform into the U.S. veterinary healthcare market, with its exclusive licensing partner commencing a development programme focused initially on companion-animal oncology and chronic pain management.
🐾 U.S. veterinary programme: Splash Beverage Group has commenced development of CannEpil® for veterinary applications through a collaboration with Lupvindol Biosciences, marking the first operational milestone since the product’s expansion into animal healthcare.
🧬 U.S. FDA pathway: The programme will initially target canine applications and progress through the U.S. FDA Center for Veterinary Medicine, beginning with the Investigational New Animal Drug process and potentially advancing towards Conditional Approval.
🇺🇸 Experienced team: Lupvindol Biosciences CEO Dr. Hunter Land, a former GW Pharmaceuticals executive involved in the development of Epidiolex® and Sativex®, will lead pharmaceutical development and regulatory strategy. Argent BioPharma retains ownership of CannEpil® intellectual property and manufacturing know-how, while participating through royalties.

"This milestone demonstrates that the global licensing strategy is already translating into tangible operational progress." – Roby Zomer, Argent BioPharma Chairman

Elk Range Mining has listed on the ASX with the ticker code of ELK. The company is a mineral explorer that owns a high-quality portfolio of gold assets located in the US state of Idaho. Its flagship asset is the Friday Gold Mine, which is positioned within one of the US’s most prospective and historically productive gold districts. Elk Range Mining also owns the Orogrande Processing Plant and associated infrastructure, which provides the Company with strategic and commercial optionality as its development strategy is delivered. Proceeds from the IPO raise will support Elk Range Mining’s planned exploration and development activities, including resource growth drilling, technical studies and permitting.

Media: The Stock Network, Lel Smits